These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 9487590

  • 21. Bench to bedside development of GMP grade Rhenium-188-HEDP, a radiopharmaceutical for targeted treatment of painful bone metastases.
    ter Heine R, Lange R, Breukels OB, Bloemendal HJ, Rummenie RG, Wakker AM, de Graaf H, Beekman FJ, van der Westerlaken MM, Malingré MM, Wielders JP, van den Berg L, Hendrikse NH, de Klerk JM.
    Int J Pharm; 2014 Apr 25; 465(1-2):317-24. PubMed ID: 24560635
    [Abstract] [Full Text] [Related]

  • 22. Treatment of painful bone metastases in prostate and breast cancer patients with the therapeutic radiopharmaceutical rhenium-188-HEDP. Clinical benefit in a real-world study.
    Lange R, Overbeek F, de Klerk JM, Pasker-de Jong PC, van den Berk AM, Ter Heine R, Rodenburg CJ, Kooistra A, Hendrikse NH, Bloemendal HJ.
    Nuklearmedizin; 2016 Sep 26; 55(5):188-95. PubMed ID: 27443809
    [Abstract] [Full Text] [Related]

  • 23. 186Re-etidronate. Efficacy of palliative radionuclide therapy for painful bone metastases.
    Han SH, De Klerk JM, Zonnenberg BA, Tan S, Van Rijk PP.
    Q J Nucl Med; 2001 Mar 26; 45(1):84-90. PubMed ID: 11456380
    [Abstract] [Full Text] [Related]

  • 24. Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer.
    de Klerk JM, Zonnenberg BA, van het Schip AD, van Dijk A, Han SH, Quirijnen JM, Blijham GH, van Rijk PP.
    Eur J Nucl Med; 1994 Oct 26; 21(10):1114-20. PubMed ID: 7530199
    [Abstract] [Full Text] [Related]

  • 25. Evaluation of toxicity and efficacy of 186Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer.
    Kolesnikov-Gauthier H, Carpentier P, Depreux P, Vennin P, Caty A, Sulman C.
    J Nucl Med; 2000 Oct 26; 41(10):1689-94. PubMed ID: 11037999
    [Abstract] [Full Text] [Related]

  • 26. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate.
    Palmedo H, Manka-Waluch A, Albers P, Schmidt-Wolf IG, Reinhardt M, Ezziddin S, Joe A, Roedel R, Fimmers R, Knapp FF, Guhlke S, Biersack HJ.
    J Clin Oncol; 2003 Aug 01; 21(15):2869-75. PubMed ID: 12885803
    [Abstract] [Full Text] [Related]

  • 27. Treatment of metastatic bone pain using the bone seeking radiopharmaceutical Re-186-HEDP.
    De Klerk JM, Zonnenberg BA, Blijham GH, Van Het Schip AD, Hoekstra A, Han SH, Quirijnen JM, Van Dijk A, Van Rijk PP.
    Anticancer Res; 1997 Aug 01; 17(3B):1773-7. PubMed ID: 9179233
    [Abstract] [Full Text] [Related]

  • 28. Palliative therapy using rhenium-186-HEDP in painful breast osseous metastases.
    Limouris GS, Shukla SK, Condi-Paphiti A, Gennatas C, Kouvaris I, Vitoratos N, Manetou A, Dardoufas C, Rigas V, Vlahos L.
    Anticancer Res; 1997 Aug 01; 17(3B):1767-72. PubMed ID: 9179232
    [Abstract] [Full Text] [Related]

  • 29. [Pain therapy in multiple bone metastases in breast carcinoma with rhenium 186 HEDP].
    Hauswirth AE, Palmedo H, Dierke-Dzierzon C, Biersack HJ, Krebs D.
    Zentralbl Gynakol; 1998 Aug 01; 120(2):83-6. PubMed ID: 9531713
    [Abstract] [Full Text] [Related]

  • 30. Radiation dose estimates of 186Re-hydroxyethylidene diphosphonate for palliation of metastatic osseous lesions: an animal model study.
    van Aswegen A, Roodt A, Marais J, Botha JM, Naudé H, Lötter MG, Goedhals L, Doman MJ, Otto AC.
    Nucl Med Commun; 1997 Jun 01; 18(6):582-8. PubMed ID: 9259533
    [Abstract] [Full Text] [Related]

  • 31. Rhenium-188-HEDP therapy for the palliation of pain due to osseous metastases in lung cancer patients.
    Zhang H, Tian M, Li S, Liu J, Tanada S, Endo K.
    Cancer Biother Radiopharm; 2003 Oct 01; 18(5):719-26. PubMed ID: 14629820
    [Abstract] [Full Text] [Related]

  • 32. Rhenium-188-HEDP in the palliative treatment of bone metastases.
    Liepe K, Hliscs R, Kropp J, Grüning T, Runge R, Koch R, Knapp FF, Franke WG.
    Cancer Biother Radiopharm; 2000 Jun 01; 15(3):261-5. PubMed ID: 10941533
    [Abstract] [Full Text] [Related]

  • 33. [Clinical experience with rhenium-188 HEDP therapy for metastatic bone pain].
    Róka R, Séra T, Pajor L, Thurzó L, Láng J, Csernay L, Pávics L.
    Orv Hetil; 2000 May 07; 141(19):1019-23. PubMed ID: 10846424
    [Abstract] [Full Text] [Related]

  • 34. Management of metastatic bone pain with repeated doses of rhenium 186-HEDP in patients under therapy with zoledronic acid: a safe and additively effective practice.
    Zafeirakis A, Zissimopoulos A, Baziotis N, Limouris GS.
    Cancer Biother Radiopharm; 2009 Oct 07; 24(5):543-50. PubMed ID: 19877884
    [Abstract] [Full Text] [Related]

  • 35. Pain palliation with rhenium-186 HEDP in breast cancer patients with disseminated bone metastases.
    Palmedo H, Bender H, Dierke-Dzierzon C, Carl UM, Risse J, Krebs D, Biersack HJ.
    Clin Nucl Med; 1999 Sep 07; 24(9):643-8. PubMed ID: 10478737
    [Abstract] [Full Text] [Related]

  • 36. A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer.
    Buffa FM, Flux GD, Guy MJ, O'Sullivan JM, McCready VR, Chittenden SJ, Dearnaley DP.
    Eur J Nucl Med Mol Imaging; 2003 Aug 07; 30(8):1114-24. PubMed ID: 12761596
    [Abstract] [Full Text] [Related]

  • 37. Rhenium-188 HEDP to treat painful bone metastases.
    Li S, Liu J, Zhang H, Tian M, Wang J, Zheng X.
    Clin Nucl Med; 2001 Nov 07; 26(11):919-22. PubMed ID: 11595844
    [Abstract] [Full Text] [Related]

  • 38. [186Re]HEDP in the palliation of painful bone metastases from cancers other than prostate and breast.
    Minutoli F, Herberg A, Spadaro P, Restifo Pecorella G, Baldari S, Aricò D, Altavilla G, Baldari S.
    Q J Nucl Med Mol Imaging; 2006 Dec 07; 50(4):355-62. PubMed ID: 17043634
    [Abstract] [Full Text] [Related]

  • 39. Serum hemoglobin levels predict response to strontium-89 and rhenium-186-HEDP radionuclide treatment for painful osseous metastases in prostate cancer.
    van der Poel HG, Antonini N, Hoefnagel CA, Horenblas S, Valdes Olmos RA.
    Urol Int; 2006 Dec 07; 77(1):50-6. PubMed ID: 16825816
    [Abstract] [Full Text] [Related]

  • 40. The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study.
    Han SH, de Klerk JM, Tan S, van het Schip AD, Derksen BH, van Dijk A, Kruitwagen CL, Blijham GH, van Rijk PP, Zonnenberg BA.
    J Nucl Med; 2002 Sep 07; 43(9):1150-6. PubMed ID: 12215552
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.